comparemela.com
Home
Live Updates
Treatment Emergent Adverse Events Considered Mild - Breaking News
Pages:
Latest Breaking News On - Treatment emergent adverse events considered mild - Page 1 : comparemela.com
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight.
Drug administration
Nasdaq
Ligand pharmaceuticals incorporated
Therapeutics inc
Study achieves primary
Secondary endpoints
Body weight
Placebo adjusted mean weight loss
From baseline
Observed after
Week study
Treatment emergent adverse events considered mild
Call scheduled
Viking therapeutics
Body weight following
Once weekly dosing
vimarsana © 2020. All Rights Reserved.